Table 1.
Influence of gene polymorphisms on new therapies in multiple sclerosis.
| Therapy | Gene | Population | N | Pathology | SNP | p-Value | OR (95% CI) | Genotype Associated | PMID |
|---|---|---|---|---|---|---|---|---|---|
| Dimethyl fumarate | ZMIZ1 | Caucasian | 39 | MS | rs1782645 | 0.031 | - | - | 28063629 |
| NOX3 | Caucasian | 564 | RRMS | rs6919626 | 0.036 | 1.57 | G | 31300673 | |
| Teriflunomide | ABCG2 | Asian | 24 | Healthy Subjects | rs2231142 | 0.004 | - | C | 20972558 |
| DHODH | Caucasian | 147 | Rheumatoid Arthritis | rs3213422 | 0.048 | 1.98 (1.00–3.94) | C | 19207032 | |
| Natalizumab | GSTP1 | Caucasian | 129 | MS | rs1695 | 0.861 | - | A | 27993870 |
| ITGA4 | Caucasian | 117 | MS | rs1143676 | 0.024 | 1.73 (1.07–2.81) | AG | 25958306 | |
| NQO1 | Caucasian | 124 | MS | rs1800566 | 0.068 | C | 27993870 | ||
| AKT1 | Caucasian | 67 | RRMS | rs2498804 | <0.01 | 11.79 (3.72–37.38) | T | 22577119 | |
| GP6 | Asian | 67 | MS | rs2304166 | <0.01 | 22.18 (5.76–95.88) | C | 20644114 | |
| Fingolimod | ZMIZ1 | Caucasian | 39 | MS | rs1782645 | 0.039 | - | - | 29435643 |
| Alemtuzumab | FCGR2A FCGR3A |
Caucasian | 85 | RRMS | rs396991 rs1801274 |
>0.05 | - | - | 31682087 |
| CD52 | Caucasian | 108 | Kidney transplant | rs107184 rs17645 |
- | - | - | 20349607 | |
| Cladribine | RRM1 | Caucasian African ancestry | 90 | Myeloid leukemia | rs11030918 | 0.04 | - | - | 24024897 |
| rs12806698 | 0.0004 | - | - | ||||||
| RRM2 | rs1042927 | 0.030 | - | - | |||||
| rs1138729 | 0.001 | - | - | ||||||
| ADA | Caucasian | 561 | RRMS | rs244072 | 0.011 | - | C | 33007809 | |
| Siponimod | CYP2C9 | - | - | MS | CYP2C9*1/*1 CYP2C9*2/*2 CYP2C9*3/*3 |
- | - | CYP2C9*3/*3 | 24024897 |
| Ocrelizumab | - | - | - | - | - | - | - | - | - |